RCW
ABBV icon

Rheos Capital Works’s AbbVie ABBV Stock Holding History

Rheos Capital Works’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.1M Buy
+60,000
New +$12.9M 0.86% 48

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Rheos Capital Works's ABBV Position: Q2 2026 in Review

Rheos Capital Works opened a new position in AbbVie (ABBV) in Q2 2026: 60,000 shares worth $15.1M. The stake represents 0.86% of the portfolio and ranks #48 among its holdings.

4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Rheos Capital Works held 60,000 shares of AbbVie worth $15.1M as of Q2 2026.
  • AbbVie was a new Rheos Capital Works position in Q2 2026.
  • AbbVie made up 0.86% of Rheos Capital Works's portfolio in Q2 2026, its #48 holding.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Rheos Capital Works's 13F filing for Q2 2026, filed 7 Aug 2026.